EPAS1 and renal cell carcinoma: Recently, PT-2385 has been tested in phase I clinical trials for RCC therapy [161], but common adverse reactions have been related to its antitumoral effect, such as anemia, edema, and fatigue, as well as HIF-2α gene mutation in some cases [161].